Anti-allergic potential of oligomannose-coated liposome-entrapped Cry j 1 as immunotherapy for Japanese cedar pollinosis in mice

Ishii, Mariko; Koyama, Aki; Iseki, Hiroshi; Narumi, Hideki; Yokoyama, Naoki; Kojima, Naoya

doi:10.1016/j.intimp.2010.06.003

Cited by 25 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A promising anti-allergic effect of an OML-based vaccine has been demonstrated in an animal model for Japanese cedar pollinosis (16). Immunization of OMLs with entrapped Cry j 1, which has been identified as a major allergen in Japanese cedar pollen, prevents elevation of the serum IgE level elicited by Cry j 1 administration in both unsensitized mice and Cry j 1-presensitized mice (Fig.…”

Section: G Therapeutic Spplication Of Oml-based Vaccinesmentioning

confidence: 94%

“…We have recently developed a new technology for control of diseases such as protozoan infectious diseases, cancer and allergy using oligomannose-coated liposomes (OMLs) as antigen carriers (13)(14)(15)(16). This approach relies on the preferential recognition of oligomannose residues on OMLs by APCs with APC-specific mannose-binding lectin receptors, and subsequent uptake of OMLs and presentation of antigens encased in the OMLs on MHC class I and class II molecules (17).…”

Section: A Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of Novel Carbohydrate-Coated Liposome-Based Vaccines

Kojima

Kawauchi

Ishii

2011

TIGG

Self Cite

View full text Add to dashboard Cite

Antigen delivery systems are important for inducing and modifying immune responses. A key to development of vaccines is the ability to deliver antigens to antigenpresenting cells (APCs) more efficiently and to induce subsequent activation of T cell-mediated immunity. Thus, strategies that target APCs and modulate APC functions in vivo have significant implications for vaccine design. We have demonstrated that oligomannose-coated liposomes (OMLs), which consist of DPPC, cholesterol, Man3-DPPE at a molar ratio of 10:10:1, can induce strong cellular immunity. In this review, we discuss OMLs as novel antigen-delivery vehicles that also have a strong adjuvant effect on induction of Th1 immune responses and CTLs specific for the encased antigen. This property of OMLs is due to their ability to assist specific cellular uptake in vivo and to promote subsequent APC maturation, presentation of antigens on APCs, preferential secretion of IL-12 from APCs, and migration of APCs into lymphoid tissues from peripheral tissues. Administration of an OML-based vaccine can eliminate an established tumor, inhibit elevation of the serum level of IgE against an allergen, and prevent progression of some protozoan infections in mouse models. In addition, OMLs with an encased antigen are able to induce antigen-specific CTLs in PBMCs obtained from patients. These feasibility studies of OML-based vaccines have revealed their potential for clinical use in vaccination for diseases in which CTLs and/or Th1 cells act as effector cells.

show abstract

Section: G Therapeutic Spplication Of Oml-based Vaccinesmentioning

confidence: 94%

Section: A Introductionmentioning

confidence: 99%

Development of Novel Carbohydrate-Coated Liposome-Based Vaccines

Kojima

Kawauchi

Ishii

2011

TIGG

Self Cite

View full text Add to dashboard Cite

show abstract

“…[31][32][33][34] OMLs were prepared from dipalmitoylphosphatidylethanolcholine, cholesterol, and mannotriose-dipalmitoylphosphatidylethanolamine at a molar ratio of 10:10:1 and extruded through a 1-µm pore membrane ( Figure 1). This approach relies on the preferential recognition of oligomannose residues on OMLs by APCs expressing APC-specific mannose-binding lectin receptors, and subsequent uptake of OMLs and antigens encased in the OMLs to be loaded on MHC class I and class II molecules.…”

Section: Oligomannose-coated Liposomes As a Drug Delivery Systemmentioning

confidence: 99%

“…These inhibitory effects may occur due to a shift from Th2 immune responses to allergen-specific Th1 immune responses since Cry j 1-specific IgG1 production mediated by Th2 cells was significantly reduced, but Cry j 1-specific IgG2a production mediated by Th1 cells increased in the sera of OML-based vaccinated mice. 31 Nasal administration of OMLs can induce entrapped HA-specific secretory IgA in local tissues and OVA-specific serum IgG and IgA. 40 These feasibility studies of OML-based vaccines have revealed their potential for clinical use as vaccinations for diseases where CTLs and/or Th1 cells are effectors.…”

Section: Oligomannose-coated Liposomes As a Therapeutic Vaccinementioning

confidence: 99%

Liposomes and nanotechnology in drug development: focus on oncotargets

Kozako¹,

Arima²,

Yoshimitsu³

et al. 2012

IJN

View full text Add to dashboard Cite

Nanotechnology is the development of an engineered device at the atomic, molecular, and macromolecular level in the nanometer range. Advances in nanotechnology have proven beneficial in therapeutic fields such as drug-delivery and gene/protein delivery. Antigen delivery systems are important for inducing and modifying immune responses. In cellular immunity, cytotoxic T lymphocytes (CTLs) are important in the host defense against tumors. Key to the development of CTL-inducible vaccines is the ability to deliver antigens to antigen-presenting cells efficiently and to induce the subsequent activation of T cell-mediated immunity without adjuvants, as they can induce excessive inflammation leading to systemic febrile disease. Since expression and cloning methods for tumor-associated antigens have been reported, cancer vaccines that induce effective cell immunity may be promising therapeutic candidates, but Th2 cells are undesirable for use in cancer immunotherapy. Peptide vaccines have immunological and economic advantages as cancer vaccines because CTL epitope peptides from tumorassociated antigens have high antigen-specificity. However, cancer vaccines have had limited effectiveness in clinical responses due to the ability of cancer cells to "escape" from cancer immunity and a low efficiency of antigen-specific CTL induction due to immunogenic-free synthetic peptides. In contrast, carbohydrate-decorated particles such as carbohydrate-coated liposomes with encapsulated antigens might be more suitable as antigen delivery vehicles to antigen-presenting cells. Oligomannose-coated liposomes (OML) can eliminate established tumors in mouse cancer models. In addition, OMLs with an encased antigen can induce antigenspecific CTLs from peripheral blood mononuclear cells obtained from patients. Feasibility studies of OML-based vaccines have revealed their potential for clinical use as vaccines for diseases where CTLs act as effector cells. Furthermore, use of the hepatitis B core particle, in which tumor-antigen epitopes are set, has consistently been shown to induce strong CTL responses without the use of an adjuvant. Thus, nanoparticles may provide a new prophylactic strategy for infectious disease and therapeutic approaches for cancer via the induction of T-cell immunity.

show abstract

“…The pre-treatment of unsensitized mice with Cry j 1/ OMLs blocked total and allergen-specific IgE levels in sera from Cry j 1 sensitized animals, with decreased IgG1 as well and significantly increased levels of specific IgG2a. [66][67][68] Liposome-protamine-DNA (LPD) NPs are safe, effective, and non-toxic adjuvants that induce Th1-like immune responses. Nouri et al demonstrated that the encapsulation of rChe a 1, rChe a 2, and rChe a 3 allergens (produced in a recombinant hybrid form [rHM]) from Chenopodium album resulted in a reduction in specific IgE and a marked increase in IgG2a in a murine model.…”

mentioning

confidence: 99%

Nanoparticle–allergen complexes for allergen immunotherapy

Felice¹,

Colombo²

2017

IJN

View full text Add to dashboard Cite

Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines.

show abstract

Anti-allergic potential of oligomannose-coated liposome-entrapped Cry j 1 as immunotherapy for Japanese cedar pollinosis in mice

Cited by 25 publications

References 29 publications

Development of Novel Carbohydrate-Coated Liposome-Based Vaccines

Development of Novel Carbohydrate-Coated Liposome-Based Vaccines

Liposomes and nanotechnology in drug development: focus on oncotargets

Nanoparticle–allergen complexes for allergen immunotherapy

Contact Info

Product

Resources

About

Anti-allergic potential of oligomannose-coated liposome-entrapped Cry j 1 as immunotherapy for Japanese cedar pollinosis in mice

Cited by 25 publications

References 29 publications

Development of Novel Carbohydrate-Coated Liposome-Based Vaccines

Development of Novel Carbohydrate-Coated Liposome-Based Vaccines

Liposomes and nanotechnology in drug development: focus on oncotargets

Nanoparticle&ndash;allergen complexes for allergen immunotherapy

Contact Info

Product

Resources

About

Nanoparticle–allergen complexes for allergen immunotherapy